Developer docs
API playgroundTry for free, no card

Search company profiles

Inversago Pharma

Full company profile

uuid0000lsu

Namestring
Inversago Pharma
Legal namestring
Inversago Pharma
Websiteurl
inversago.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Inversago Pharma was a privately-held, clinical-stage biopharmaceutical company headquartered in Montréal, Quebec, Canada, focused on developing a portfolio of peripherally-acting CB1 (cannabinoid receptor type 1) inverse agonists for metabolic and fibrotic disorders. Founded in 2015 and operating with 11–50 employees, the company's lead clinical asset was INV-202, a peripheral CB1 receptor blocker advancing through Phase 2 clinical trials for Diabetic Kidney Disease (DKD), with additional pre-clinical programs targeting obesity and related metabolic conditions. The company's core technological differentiator was its emphasis on peripheral (non-CNS-penetrant) CB1 blockade, which was positioned to preserve the metabolic benefits of CB1 antagonism while avoiding the psychiatric adverse effects that had derailed earlier CNS-active CB1 antagonists.

The business model was characteristic of a pre-commercial, capital-intensive clinical biotech: revenue was not generated from product sales; instead, the company was funded through successive venture equity rounds — a $7M Series A (July 2018) co-led by Amorchem and Genesys Capital, a $35M Series B (September 2020) co-led by Fonds de solidarité FTQ and Forbion Capital Partners, and a $95M CAD (~$69M USD) Series C (October 2022) led by New Enterprise Associates with participation from Forbion and Amgen Ventures. Cumulative capital raised was approximately $111M (USD-equivalent), deployed into R&D, clinical operations, and pre-clinical pipeline expansion. No pricing model, marketed product, or paying customer base existed during standalone operations.

In August 2023, Novo Nordisk A/S acquired Inversago Pharma for up to US$1.08 billion to strengthen its obesity and metabolic disorder pipeline with Inversago's CB1 blocker programs, including INV-202. Following the acquisition, Inversago ceased to operate as an independent entity; its website (inversago.com) is no longer resolvable, and the company's assets and programs have been folded into Novo Nordisk's portfolio. The Inversago brand, pipeline, and team no longer operate on a standalone basis.

Short descriptiontext

Inversago Pharma was a Canadian clinical-stage biotech developing peripheral CB1 receptor blockers for metabolic disorders, with lead asset INV-202 in Phase 2 trials for Diabetic Kidney Disease before its August 2023 acquisition by Novo Nordisk for up to $1.08B.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontréal, Canada
HQ citystring
Montréal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, CB1 receptor blockers, metabolic disorder therapeutics, diabetic kidney disease treatment, cannabinoid receptor antagonists
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
No data
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Inversago Pharma develops peripheral CB1 receptor blocker (inverse agonist) therapies for metabolic and fibrotic disorders. Its lead clinical candidate, INV-202, is in Phase 2 clinical trials for Diabetic Kidney Disease. The company focuses on small-molecule drug discovery and clinical development rather than commercial manufacturing or sale of approved products.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Inversago Pharma was a Canadian clinical-stage biopharmaceutical company focused on developing CB1 (cannabinoid receptor type 1) blocker therapies. The company's lead product was INV-202, which was advancing through Phase 2 clinical trials for Diabetic Kidney Disease. In August 2023, the company was acquired by Novo Nordisk A/S for up to US$1.08 billion.

Product and service1 record
1INV-202
CategorySmall-molecule therapeutic candidate
Description

INV-202 is a peripheral CB1 receptor blocker (inverse agonist) being clinically evaluated for Diabetic Kidney Disease; it is Inversago Pharma's lead clinical-stage therapeutic candidate.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Novo Nordisk acquired Inversago Pharma in August 2023 for up to US$1.08 billion to strengthen its obesity and metabolic disorder pipeline with Inversago's CB1 blocker programs including INV-202.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Commercial-stage rare disease company with Filspari approved for IgA nephropathy, making it a relevant peer in the kidney disease therapeutics market that Inversago's INV-202 is targeting.

TypeEmerging player
Description

Clinical-stage cell therapy company focused on diabetic kidney disease, directly comparable to INV-202's lead indication and representing a parallel approach (cell therapy vs. small-molecule CB1) to DKD.

3Goldfinch Bio
TypeEmerging player
Description

Clinical-stage nephrology company focused on precision medicines for kidney disease, comparable as a peer in kidney-focused biotech drug development where Inversago's INV-202 operates.

TypeEmerging player
Description

Clinical-stage precision medicine company with programs targeting kidney and metabolic diseases, including genetic forms of kidney disease, sharing the metabolic/kidney therapeutic development focus.

TypeEmerging player
Description

Clinical-stage biotech developing treatments for hematological and musculoskeletal disorders with metabolic signaling modulation; comparable as a small-cap clinical-stage biotech with innovative mechanism-based programs.

TypeEmerging player
Description

Clinical-stage biotech developing controlled metabolic accelerators (mitochondrial uncouplers) for obesity and metabolic liver disease, representing a parallel emerging approach to metabolic disease.

TypeBroad incumbent
Description

Commercial-stage metabolic disease company focused on lipid-lowering therapies; comparable as a small-cap metabolic-focused biotech developing innovative cardiovascular/metabolic treatments.

TypeEmerging player
Description

Clinical-stage nephrology company developing precision medicines for rare kidney diseases including IgA nephropathy, a direct peer in the kidney disease drug development space where Inversago's INV-202 is positioned.

TypeDirect peer
Description

Clinical-stage biotech developing cannabinoid receptor-targeting therapeutics, including CB1 inverse agonists, making it the most direct mechanistic peer to Inversago's peripheral CB1 blocker approach.

TypeDirect peer
Description

Clinical-stage company developing CB1-specific signaling inhibitors (CB1-SSi) for metabolic and psychiatric disorders, sharing Inversago's focus on CB1 pharmacology with a distinct mechanistic angle.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inversago Pharma

Biopharmaceuticalsinversago.com

Inversago Pharma was a Canadian clinical-stage biotech developing peripheral CB1 receptor blockers for metabolic disorders, with lead asset INV-202 in Phase 2 trials for Diabetic Kidney Disease before its August 2023 acquisition by Novo Nordisk for up to $1.08B.

What Inversago Pharma does

Inversago Pharma was a privately-held, clinical-stage biopharmaceutical company headquartered in Montréal, Quebec, Canada, focused on developing a portfolio of peripherally-acting CB1 (cannabinoid receptor type 1) inverse agonists for metabolic and fibrotic disorders. Founded in 2015 and operating with 11–50 employees, the company's lead clinical asset was INV-202, a peripheral CB1 receptor blocker advancing through Phase 2 clinical trials for Diabetic Kidney Disease (DKD), with additional pre-clinical programs targeting obesity and related metabolic conditions. The company's core technological differentiator was its emphasis on peripheral (non-CNS-penetrant) CB1 blockade, which was positioned to preserve the metabolic benefits of CB1 antagonism while avoiding the psychiatric adverse effects that had derailed earlier CNS-active CB1 antagonists.

The business model was characteristic of a pre-commercial, capital-intensive clinical biotech: revenue was not generated from product sales; instead, the company was funded through successive venture equity rounds — a $7M Series A (July 2018) co-led by Amorchem and Genesys Capital, a $35M Series B (September 2020) co-led by Fonds de solidarité FTQ and Forbion Capital Partners, and a $95M CAD (~$69M USD) Series C (October 2022) led by New Enterprise Associates with participation from Forbion and Amgen Ventures. Cumulative capital raised was approximately $111M (USD-equivalent), deployed into R&D, clinical operations, and pre-clinical pipeline expansion. No pricing model, marketed product, or paying customer base existed during standalone operations.

In August 2023, Novo Nordisk A/S acquired Inversago Pharma for up to US$1.08 billion to strengthen its obesity and metabolic disorder pipeline with Inversago's CB1 blocker programs, including INV-202. Following the acquisition, Inversago ceased to operate as an independent entity; its website (inversago.com) is no longer resolvable, and the company's assets and programs have been folded into Novo Nordisk's portfolio. The Inversago brand, pipeline, and team no longer operate on a standalone basis.

Inversago Pharma firmographics

Firmographics
Name
Inversago Pharma
Legal name
Inversago Pharma
Website
https://inversago.com
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
11–50 employees
Short description
Inversago Pharma was a Canadian clinical-stage biotech developing peripheral CB1 receptor blockers for metabolic disorders, with lead asset INV-202 in Phase 2 trials for Diabetic Kidney Disease before its August 2023 acquisition by Novo Nordisk for up to $1.08B.
Ownership category
akta.pro rank

Inversago Pharma industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceuticals
  • CB1 receptor blockers
  • Metabolic disorder therapeutics
  • Diabetic kidney disease treatment
  • Cannabinoid receptor antagonists

Where Inversago Pharma is headquartered

Location

Headquarters

HQ city
Montréal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Inversago Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Inversago Pharma product offering

Product offering

Core offering

Inversago Pharma develops peripheral CB1 receptor blocker (inverse agonist) therapies for metabolic and fibrotic disorders. Its lead clinical candidate, INV-202, is in Phase 2 clinical trials for Diabetic Kidney Disease. The company focuses on small-molecule drug discovery and clinical development rather than commercial manufacturing or sale of approved products.

Product overview

Inversago Pharma was a Canadian clinical-stage biopharmaceutical company focused on developing CB1 (cannabinoid receptor type 1) blocker therapies. The company's lead product was INV-202, which was advancing through Phase 2 clinical trials for Diabetic Kidney Disease. In August 2023, the company was acquired by Novo Nordisk A/S for up to US$1.08 billion.

Differentiator

Problem solved

Functional benefit

Products and services

  • INV-202 INV-202 is a peripheral CB1 receptor blocker (inverse agonist) being clinically evaluated for Diabetic Kidney Disease; it is Inversago Pharma's lead clinical-stage therapeutic candidate.

Companies that use Inversago Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Inversago Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Inversago Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Novo NordiskflagshipStrategic or Co-development Partner · 1 August 2023Novo Nordisk acquired Inversago Pharma in August 2023 for up to US$1.08 billion to strengthen its obesity and metabolic disorder pipeline with Inversago's CB1 blocker programs including INV-202.

Scale indicators3 records

Recent moves5 records

Expansion highlights3 records

Inversago Pharma competitors and assessment

Company assessment

Emerging players

  • Travere Therapeutics: Commercial-stage rare disease company with Filspari approved for IgA nephropathy, making it a relevant peer in the kidney disease therapeutics market that Inversago's INV-202 is targeting.
  • ProKidney: Clinical-stage cell therapy company focused on diabetic kidney disease, directly comparable to INV-202's lead indication and representing a parallel approach (cell therapy vs. small-molecule CB1) to DKD.
  • Goldfinch Bio: Clinical-stage nephrology company focused on precision medicines for kidney disease, comparable as a peer in kidney-focused biotech drug development where Inversago's INV-202 operates.
  • Maze Therapeutics: Clinical-stage precision medicine company with programs targeting kidney and metabolic diseases, including genetic forms of kidney disease, sharing the metabolic/kidney therapeutic development focus.
  • Keros Therapeutics: Clinical-stage biotech developing treatments for hematological and musculoskeletal disorders with metabolic signaling modulation; comparable as a small-cap clinical-stage biotech with innovative mechanism-based programs.
  • Rivus Pharmaceuticals: Clinical-stage biotech developing controlled metabolic accelerators (mitochondrial uncouplers) for obesity and metabolic liver disease, representing a parallel emerging approach to metabolic disease.
  • Chinook Therapeutics: Clinical-stage nephrology company developing precision medicines for rare kidney diseases including IgA nephropathy, a direct peer in the kidney disease drug development space where Inversago's INV-202 is positioned.

Broad incumbents

  • Esperion Therapeutics: Commercial-stage metabolic disease company focused on lipid-lowering therapies; comparable as a small-cap metabolic-focused biotech developing innovative cardiovascular/metabolic treatments.

Direct peers

  • Corbus Pharmaceuticals: Clinical-stage biotech developing cannabinoid receptor-targeting therapeutics, including CB1 inverse agonists, making it the most direct mechanistic peer to Inversago's peripheral CB1 blocker approach.
  • Aelis Farma: Clinical-stage company developing CB1-specific signaling inhibitors (CB1-SSi) for metabolic and psychiatric disorders, sharing Inversago's focus on CB1 pharmacology with a distinct mechanistic angle.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Inversago Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inversago Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Inversago Pharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inversago Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inversago Pharma

What does Inversago Pharma do?

Inversago Pharma develops peripheral CB1 receptor blocker (inverse agonist) therapies for metabolic and fibrotic disorders. Its lead clinical candidate, INV-202, is in Phase 2 clinical trials for Diabetic Kidney Disease. The company focuses on small-molecule drug discovery and clinical development rather than commercial manufacturing or sale of approved products.

Is Inversago Pharma a public or private company?

Inversago Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was Inversago Pharma founded?

Inversago Pharma was founded in 2015. It employs 11 to 50 people.

Where is Inversago Pharma based?

Inversago Pharma is headquartered in Montréal, Canada, in the North America region.

Who are Inversago Pharma's main competitors?

Emerging players on record are Travere Therapeutics, ProKidney, Goldfinch Bio, Maze Therapeutics, Keros Therapeutics, Rivus Pharmaceuticals and Chinook Therapeutics. Esperion Therapeutics is listed as a broad incumbent. Direct peers are Corbus Pharmaceuticals and Aelis Farma.

Does Inversago Pharma have an API?

No public API is recorded for Inversago Pharma.

What industry is Inversago Pharma in?

Inversago Pharma's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BorsenNovo har brugt milliarder på fejlslagne opkøb – se listenNovo Nordisk has abandoned half of the 16 pharmaceutical acquisitions it made over the last decade, with recent examples including the cancellation of its 2023 purchase of biotech firm Inversago. The company's CFO publicly acknowledged this poor track record of failed investments.pharmaphorumNovo fails to shrug off investor concern at Q2 updateNovo Nordisk reported Q2 revenue of DKK 78.5 billion, up 3%, and raised its full-year guidance, but shares fell over 12% on investor concerns. Wegovy's weekly prescriptions reached 265,000, and CagriSema failed to show non-inferiority to Lilly's Zepbound in a phase 3 trial. The company also abandoned monlunabant development, adding to pressure on its pipeline.FierceBiotechNovo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataNovo Nordisk's CEO acknowledged recent R&D setbacks after CagriSema missed one of its phase 3 endpoints, showing non-inferiority to Eli Lilly's tirzepatide for weight loss (15.2% vs 15.8%) but failing to match its blood sugar control in the Reimagine-4 study. The company's cardiovascular candidate ziltivekimab also failed to demonstrate significant reduction in major adverse cardiovascular events in a separate phase 3 trial, while Novo has abandoned the monlunabant program from its failed $1.1 billion acquisition of Inversago Pharma due to unacceptable safety concerns. Despite these setbacks, Novo has submitted CagriSema for FDA approval and is actively seeking bolt-on acquisitions to complement its pipeline.BorsenInvestor om Novos vækstjagt: Opkøb er en farlig strategiNovo Nordisk is facing investor criticism over its acquisition-based growth strategy as the patent cliff on semaglutide approaches, with Ole Søeberg of Brock Milton Capital calling acquisitions a risky path and preferring organic growth. The company recorded a 6.3 billion DKK write-down tied to failed acquisitions including the weight-loss drug monlunabant from Inversago Pharmaceuticals and the phase-3-failed cardiovascular candidate ziltivekimab from Corvidia Therapeutics, whose 2020 acquisition cost 725 million USD. Following the July 31 phase 3 failure of ziltivekimab, Novo Nordisk lost 150 billion DKK in market value in a single day, underscoring the destruction of value from its M&A activity.openPR.comAnalysis of Key Market Segments Influencing the Metabolic Syndrome MarketThe metabolic syndrome market is projected to reach $127.96 billion by 2030, growing at a compound annual growth rate of 7.2%, driven by digital therapeutics, AI-based metabolic assessment tools, and remote monitoring innovations. In August 2023, Denmark-based Novo Nordisk A/S acquired Inversago Pharma, a Canadian clinical-stage biopharmaceutical firm, for an undisclosed sum to strengthen its obesity and metabolic disorder pipeline. US-based VivaLNK Inc. also introduced a 14-day live stream wearable ECG patch in 2023 for continuous cardiac monitoring.PR NewswireWearable Devices and IoT Revolutionize Healthcare Monitoring and Weight ManagementThis market commentary examines how wearable devices and IoT technology are transforming healthcare monitoring and weight management, highlighting multiple corporate developments across the sector. Nemaura Medical announced interim results from its Miboko metabolic health program showing that 59 of 83 participants achieved weight loss averaging 2.9KG over 20 weeks using daily-wear continuous glucose sensors paired with an AI-driven app, achieving a 64% user intent-to-continue rate that significantly exceeds industry benchmarks. Meanwhile, Planet Fitness announced a collaboration with Amazon Halo to offer complimentary fitness trackers to new members, Xponential Fitness renewed its partnership with lululemon to expand digital workouts, Novo Nordisk agreed to acquire Inversago Pharma for up to $1.075 billion to strengthen its obesity treatment pipeline, and Abbott Laboratories received FDA approval for the world's first dual-chamber leadless pacemaker system.MarketScreenerNovo Nordisk A/S (CPSE:NOVO B) completed the acquisition of Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovaNovo Nordisk A/S completed the acquisition of Inversago Pharma Inc. for an initial $1 billion, with potential additional milestone payments bringing the total value to up to $1.075 billion. The deal includes Inversago's lead asset INV-202 and was finalized on September 8, 2023, following regulatory approvals.PharmiWeb.comNovo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseasesNovo Nordisk has agreed to acquire Inversago Pharma for up to 1.075 billion US dollars, contingent on achieving specific development and commercial milestones. Inversago is developing therapies targeting obesity and diabetes, with its lead asset INV-202 currently in phase 2 trials for diabetic kidney disease. The acquisition aims to enhance Novo Nordisk's clinical pipeline for treating serious metabolic disorders.Express PharmaNovo Nordisk to acquire Inversago Pharma for up to $1.075 bnNovo Nordisk has agreed to acquire Inversago Pharma for up to $1.075 billion in cash, contingent on the achievement of specific development and commercial milestones. The deal includes Inversago’s lead asset INV-202, an oral CB1 inverse agonist currently in Phase 2 trials for diabetic kidney disease, which Novo Nordisk intends to further investigate for obesity treatment. The acquisition is expected to close before the end of 2023, subject to regulatory approvals.GlobeNewswireNovo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseasesNovo Nordisk agreed to acquire Inversago Pharma for up to $1.075 billion in cash, subject to milestones. The deal includes Inversago's lead asset INV-202, an oral CB1 inverse agonist in phase 2 for diabetic kidney disease. Closing is expected before end of 2023.